Lupus Nephritis

Immunology·MeSH: Lupus Nephritis

34 drugs in development·19 companies·26 clinical trials

Drug Pipeline by Phase

Phase 3(6)

Drug	Company
ANX009	Annexon, Inc. (ANNX)
chemotherapy agents	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
ianalumab s.c. q12w	Novartis AG (NVS)
ianalumab s.c. q12w	Novartis AG (NVS)
ianalumab s.c. q4w	Novartis AG (NVS)
voclosporin	Aurinia Pharmaceuticals Inc. (AUPH)

Phase 2(6)

Drug	Company
AKB-097	Akebia Therapeutics, Inc. (AKBA)
Atacicept	Vera Therapeutics, Inc. (VERA)
kzr-616	Kezar Life Sciences, Inc. (KZR)
ra101495 sc	RA PHARMACEUTICALS, INC. (RARX)
rese-cel	Cabaletta Bio, Inc. (CABA)
zetomipzomib	Kezar Life Sciences, Inc. (KZR)

Phase 1(6)

Drug	Company
ADI-001	Adicet Bio, Inc. (ACET)
fludarabine	CELLULAR BIOMEDICINE GROUP, INC. (CMBG)
prula-cel	Adicet Bio, Inc. (ACET)
rese-cel (resecabtagene autoleucel)	Cabaletta Bio, Inc. (CABA)
vonsetamig	REGENERON PHARMACEUTICALS, INC. (REGN)
zamtocabtagene autoleucel	CELLULAR BIOMEDICINE GROUP, INC. (CMBG)

Preclinical(2)

Drug	Company
gri-0803	GRI Bio, Inc. (GRI)
tavneos	ChemoCentryx, Inc. (CCXI)

Unknown(1)

Drug	Company
LUPKYNIS	UNITED THERAPEUTICS Corp (UTHR)

Phase 1/Phase 2(3)

Drug	Company
fludarabine	Nkarta, Inc. (NKTX)
nkx019	Nkarta, Inc. (NKTX)
povetacicept	ALPINE IMMUNE SCIENCES, INC. (ALPN)

Phase 2/Phase 3(4)

Drug	Company
kyv-101	Kyverna Therapeutics, Inc. (KYTX)
kyv-101 anti-cd19 car-t cell therapy	Kyverna Therapeutics, Inc. (KYTX)
standard lymphodepletion regimen	Kyverna Therapeutics, Inc. (KYTX)
tak-007	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)

Phase 4(6)

Drug	Company
belimumab	Aurinia Pharmaceuticals Inc. (AUPH)
Efgartigimod IV	ARGENX SE (ARGX)
efgartigimod iv or efgartigimod ph20 sc	ARGENX SE (ARGX)
ianalumab s.c. q4w	Novartis AG (NVS)
LUPKYNIS	Aurinia Pharmaceuticals Inc. (AUPH)
mycophenolic acid analog	Aurinia Pharmaceuticals Inc. (AUPH)

BioSniper tracks 34 drugs in development for Lupus Nephritis across 19 companies.

There are 26 clinical trials targeting Lupus Nephritis tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.